Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | USP8 | P40818 | 1/20 | 0.56 |
| ▸ | FABP3 | P05413 | 2/20 | 0.52 |
| ▸ | FABP4 | P15090 | 1/20 | 0.52 |
| ▸ | FLT3 | P36888 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | BRAF | P15056 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.44 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.44 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14132548 | 0.90 | USP8 (0.59) | MEN1KMT2AUSP8FABP3FABP4 | |
| SCHEMBL15070238 | 0.88 | USP8 (0.57) | MEN1KMT2AUSP8FABP3FABP4 | |
| SCHEMBL4592621 | 0.83 | PTGS2 (0.52) | MEN1KMT2AFLT3PTGS2SRC | |
| SCHEMBL6780629 | 0.83 | PTGS2 (0.49) | MEN1KMT2AUSP8FABP3FABP4 | |
| SCHEMBL6780624 | 0.83 | PTGS2 (0.49) | MEN1KMT2AUSP8FLT3PTGS2 | |
| SCHEMBL3447525 | 0.82 | USP8 (0.53) | MEN1KMT2AUSP8CYP2C9PTGS1 | |
| SCHEMBL27690123 | 0.82 | USP8 (0.55) | MEN1KMT2AUSP8CYP2C9PTGS1 | |
| SCHEMBL3446365 | 0.82 | USP8 (0.55) | MEN1KMT2AUSP8FABP3FABP4 | |
| SCHEMBL10038494 | 0.81 | CYP2C9 (0.62) | MEN1KMT2AUSP8CYP2C9PTGS1 | |
| SCHEMBL16432877 | 0.81 | CYP2C9 (0.62) | MEN1KMT2AUSP8CYP2C9PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030153569-A1 | Novel pyrazole and pyrazoline substituted compounds | SMITHKLINE BEECHAM CORPORATION | 2003-08-14 | — | — | US | claimed |
| US-20020156104-A1 | CSBP/p38/RK kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-10-24 | — | — | US | claimed |
| EP-1023066-A4 | NOVEL PYRAZOLE AND PYRAZOLINE SUBSTITUTED COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2001-05-23 | — | — | EP | claimed |
| EP-1023066-A1 | NOVEL PYRAZOLE AND PYRAZOLINE SUBSTITUTED COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-08-02 | — | — | EP | claimed |
| WO-1998056377-A1 | NOVEL PYRAZOLE AND PYRAZOLINE SUBSTITUTED COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-12-17 | — | — | WO | claimed |
| EP-1539121-A4 | METHODS OF PROMOTING OSTEOGENESIS | SCIOS INC (US) | 2008-08-13 | — | — | EP | disclosed |
| US-20080108658-A1 | METHODS OF PROMOTING OSTEOGENESIS | PROTTER ANDREW A | 2008-05-08 | — | — | US | disclosed |
| EP-1583535-A4 | METHODS FOR TREATING DIABETES | SCIOS INC (US) | 2008-03-19 | — | — | EP | disclosed |
| US-20080039461-A1 | Treatment of pain by inhibition of p38 map kinase | PROTTER ANDREW A | 2008-02-14 | — | — | US | disclosed |
| US-7268139-B2 | Methods of promoting osteogenesis | SCIOS, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| US-7244441-B2 | Stents and intra-luminal prostheses containing map kinase inhibitors | SCIOS, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| EP-1676574-A2 | Methods for promoting survival of transplanted tissues and cells | Johnson & Johnson Vision Care, Inc. (US) | 2006-07-05 | — | — | EP | disclosed |
| WO-2004019873-A9 | METHODS OF PROMOTING OSTEOGENESIS | SCIOS INC (US) | 2004-06-24 | — | — | WO | disclosed |
| US-20040122008-A1 | Treatment of pain by inhibition of p38 MAP kinase | SCIOS, INC. | 2004-06-24 | — | — | US | disclosed |
| WO-2004019873-A2 | METHODS OF PROMOTING OSTEOGENESIS | SCIOS INC. (US) | 2004-03-11 | — | — | WO | disclosed |
| US-20030153569-A1 | Novel pyrazole and pyrazoline substituted compounds | SMITHKLINE BEECHAM CORPORATION | 2003-08-14 | — | — | US | disclosed |
| US-20020156104-A1 | CSBP/p38/RK kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-10-24 | — | — | US | disclosed |
| EP-1023066-A4 | NOVEL PYRAZOLE AND PYRAZOLINE SUBSTITUTED COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2001-05-23 | — | — | EP | disclosed |
| EP-1023066-A1 | NOVEL PYRAZOLE AND PYRAZOLINE SUBSTITUTED COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-08-02 | — | — | EP | disclosed |
| WO-1998056377-A1 | NOVEL PYRAZOLE AND PYRAZOLINE SUBSTITUTED COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108658-A1 | METHODS OF PROMOTING OSTEOGENESIS | MAPK1, BMP2, MAPK3 | MEN1 1366/4885KMT2A 2643/4885USP8 3929/4885 |
| US-20030153569-A1 | Novel pyrazole and pyrazoline substituted compounds | PDXK, COQ8A, PDK3 | MEN1 3265/4885KMT2A 3711/4885USP8 3733/4885 |
| US-20040122008-A1 | Treatment of pain by inhibition of p38 MAP kinase | OPRK1, OPRL1, MAPK3 | MEN1 4518/4885KMT2A 4237/4885USP8 3186/4885 |
| US-20080039461-A1 | Treatment of pain by inhibition of p38 map kinase | OPRK1, OPRL1, MAPK3 | MEN1 4518/4885KMT2A 4237/4885USP8 3186/4885 |
| US-20020156104-A1 | CSBP/p38/RK kinase inhibitors | MAPKAPK2, MAPKAPK3, MAPKAPK5 | MEN1 4619/4885KMT2A 3249/4885USP8 2008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.